(Q38127967)

29 August 2017

title

Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation (English)

1 reference

29 August 2017

V Ram Peddi

1

1 reference

29 August 2017

Alexander Wiseman

series ordinal

2

1 reference

29 August 2017

Kenneth Chavin

series ordinal

3

1 reference

29 August 2017

Douglas Slakey

series ordinal

4

1 reference

29 August 2017

publication date

8 August 2013

1 reference

29 August 2017

published in

Transplantation Reviews

1 reference

29 August 2017

volume

27

1 reference

29 August 2017

issue

4

1 reference

29 August 2017

page(s)

97-107

1 reference

KDIGO clinical practice guideline for the care of kidney transplant recipients

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Immunosuppression: towards a logical approach in liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

The natural history of chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Chronic renal failure after transplantation of a nonrenal organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

The role of the mammalian target of rapamycin (mTOR) in renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Clinical pharmacokinetics of everolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Preclinical results of sirolimus treatment in transplant models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

m-TOR inhibitors: what role in liver transplantation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Pharmacokinetics of tacrolimus-based combination therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Hypertension after kidney transplant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

The metabolic effects of cyclosporin and tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Sirolimus is associated with new-onset diabetes in kidney transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Proteinuria in kidney transplant recipients: prevalence, prognosis, and evidence-based management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Significance and management of proteinuria in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Factors associated with proteinuria in renal transplant recipients treated with sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Proteinuria after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Persistence of DNA Sequences of BK Virus and JC Virus in Normal Human Tissues and in Diseased Tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Factors influencing viral clearing and renal function during polyomavirus BK-associated nephropathy after renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

A single-centre experience of post-renal transplant lymphoproliferative disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Lymphomas after solid organ transplantation: a collaborative transplant study report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Targeting risk factors for impaired wound healing and wound complications after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Cancer incidence after immunosuppressive treatment following kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Sirolimus and secondary skin-cancer prevention in kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2013.06.001

10.1016/J.TRRE.2013.06.001

7 January 2021

Identifiers

DOI

1 reference

29 August 2017

1 reference